4d347bfa-eb25-4e9d-9594-4e1d99545678
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- P53_PATHWAY+0.350
- CHOLESTEROL_HOMEOSTASIS+0.310
- OXIDATIVE_PHOSPHORYLATION+0.250
- APOPTOSIS+0.220
- DNA_REPAIR+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- COAGULATION+0.180
- FATTY_ACID_METABOLISM+0.180
- NOTCH_SIGNALING+0.170
- ANGIOGENESIS+0.160
Top 10 suppressed
- G2M_CHECKPOINT-0.410
- E2F_TARGETS-0.400
- MITOTIC_SPINDLE-0.310
- MYC_TARGETS_V2-0.280
- HEDGEHOG_SIGNALING-0.260
- BILE_ACID_METABOLISM-0.190
- UV_RESPONSE_DN-0.180
- SPERMATOGENESIS-0.150
- ANDROGEN_RESPONSE-0.120
- PEROXISOME-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R170 | — | — | 0.686 |
| 2 | TCGA-44-4112-01A-01R-1107-07 | — | cohortA1 | 0.675 |
| 3 | BS_P78SMRBS | Spinal Cord Ependymoma | — | 0.674 |
| 4 | C3N-00578 | — | cohortA1 | 0.673 |
| 5 | TCGA-CN-4726-01A-01R-1436-07 | — | — | 0.668 |
| 6 | 17-026K4_Bladder | — | — | 0.664 |
| 7 | 4bafe83e-072c-4042-bd3d-5f108391ed89 | — | — | 0.663 |
| 8 | TCGA-A7-A3IY-01A-21R-A21T-07 | — | C | 0.663 |
| 9 | SRR8752372 | — | — | 0.660 |
| 10 | cc158c27-a2f0-4403-ae01-913bfcc623cc | — | — | 0.658 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |